IgA Nephropathy Clinical Trials

Find IgA Nephropathy Clinical Trials Near You

A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy

Status: Recruiting
Location: See all (11) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN. While in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise. The study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Males and females (not pregnant)

• At least 18 years old

• Clinically diagnosed with IgAN with biopsy confirmation

Locations
United States
California
Amicis Research Center - Valencia
RECRUITING
Valencia
Florida
Bioresearch Partners
RECRUITING
Miami
Nephrology Associates of South Miami PA
RECRUITING
Miami
BioResearch Partner - Pembroke Pines
RECRUITING
Pembroke Pines
Michigan
Michigan Kidney Consultants
RECRUITING
Pontiac
Texas
Northwest Houston Arthritis Center - Houston
NOT_YET_RECRUITING
Houston
Prolato Clinical Research Center
RECRUITING
Houston
Utah
Utah Kidney Research Institute
RECRUITING
Salt Lake City
Virginia
Kidney and Hypertension Specialists- Virginia
RECRUITING
Manassas
Other Locations
Japan
Japanese Red Cross Fukuoka Hospital
RECRUITING
Fukuoka
Sapporo City General Hospital
RECRUITING
Sapporo
Contact Information
Primary
Sabine Coppieters, MD
Clinicaltrials@argenx.com
857-350-4834
Time Frame
Start Date: 2026-11-05
Estimated Completion Date: 2030-02-18
Participants
Target number of participants: 120
Treatments
Experimental: ARGX-121
Participants will receive ARGX-121 in subcutaneous injections during the double blinded treatment period and active only treatment periods (Total of 52 weeks)
Placebo_comparator: Placebo followed by ARGX-121
Participants receive placebo for the double-blinded period of 24 weeks, followed by subcutaneous injections of ARGX-121 during the active only treatment period of 28 weeks.
Related Therapeutic Areas
Sponsors
Leads: argenx

This content was sourced from clinicaltrials.gov